ABBV vs JNJ

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). Johnson & Johnson (JNJ) offers the better valuation at 39. 0x trailing P/E (19. 5x forward), making it the more compelling value choice. Analysts rate AbbVie Inc. (ABBV) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Johnson & Johnson (JNJ) is the cheapest at 39.

0x versus AbbVie Inc. at 87. 0x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +104. 3%, compared to +49. 2% for Johnson & Johnson (JNJ). Over 10 years, the gap is even starker: ABBV returned +309. 7% versus JNJ's +136. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus AbbVie Inc. 's 0. 34β — meaning ABBV is approximately 493% more volatile than JNJ relative to the S&P 500.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: AbbVie Inc. grew EPS -0. 8% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, JNJ leads at 4. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus 6. 9% for AbbVie Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus 24. 9% for JNJ. At the gross margin level — before operating expenses — ABBV leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 5x forward P/E versus 19. 5x for Johnson & Johnson — 4. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 24. 5% to $256. 64.

All stocks in this comparison pay dividends.

AbbVie Inc. (ABBV) offers the highest yield at 3. 2%, versus 2. 2% for Johnson & Johnson (JNJ).

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +136. 8% 10Y return). Both have compounded well over 10 years (JNJ: +136. 8%, ABBV: +309. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ABBV is a large-cap income-oriented stock; JNJ is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.